Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Children and young people aged 2 to 25 years who have a low-grade brain tumour (a slow-growing type of brain tumour called LGG) that has come back or kept growing after at least one previous treatment (which may have been surgery alone or other treatments).
• The tumour must have been confirmed by a tissue sample (biopsy or surgery) and reviewed by a central team who decide whether a laser treatment called LITT is appropriate for that tumour.
• The tumour must be no larger than 5 cm at its widest point (not counting any fluid-filled cysts); larger tumours may still be considered after discussion with the study team.
• The tumour must be located in a part of the brain or nervous system that the central review team considers safe and reachable for LITT — certain tumour locations have specific conditions (confirm with trial site).
• People whose tumour has come back multiple times may still be considered, as long as other criteria are met.
• People who have had LITT before for a different reason may be eligible, as long as the specific tumour being treated in this trial has not previously had LITT — except where a tumour treated with LITT more than 15 months ago has since grown back.
• People who have recovered from the side effects of any previous chemotherapy or targeted therapy, and whose last dose of the drug bevacizumab was more than 21 days before joining the trial.
• People whose last chemotherapy treatment was more than 3 weeks before joining (or more than 6 weeks for certain specific drug types called nitrosoureas or mitomycin C).
• People who finished a biological or small molecule therapy at least 7 days before joining, and are past any known window of side effects from that treatment.
• People who finished radiation treatment to the main tumour site at least 12 weeks before joining, including full spinal or whole-body radiation if applicable.
• People with a functional ability score of at least 50 on standard medical scales used for their age group (this reflects being able to carry out some daily activities, including people who use a wheelchair but are not fully bedridden).
• People taking the steroid medication dexamethasone, provided the dose has been stable or reducing for at least one week before joining.
• People who are considered suitable for surgery under their treating hospital's standards.
• A parent, legal guardian, or the patient themselves (where appropriate) must be willing and able to sign a consent form agreeing to take part.
• Participants must also be enrolled in a linked research programme called PNOC COMP, if that programme is available at the treating hospital.

Who may not be able to join:

• People whose tumour is located on the optic pathway (the nerve structures connected to vision).
• People whose tumour is in the spine.
• People with infiltrative brainstem tumours (tumours that have spread into and through the brainstem tissue) — note that certain brainstem tumours that grow outward rather than inward may still be considered (confirm with trial site).
• People whose tumour location is determined by the central review team to be unsuitable for LITT for any reason.
• People with leptomeningeal disease (cancer spread to the fluid and membranes around the brain and spine) that is not controlled, or with tumour spread outside the brain that is not controlled.
• People with a dangerous build-up of fluid pressure in the brain (obstructive hydrocephalus) that has not been treated, or with significant shifting of brain structures caused by the tumour (more than 10 mm).
• People with significant bleeding inside the tumour causing symptoms (confirm with trial site for lesser degrees of bleeding).
• People currently taking part in another clinical trial involving an investigational (unapproved) treatment.
• People with an active, uncontrolled infection or other serious uncontrolled illness at the time of joining.

Important: Always verify eligibility with the trial site directly before applying.